17,000 Shares in Fluidigm Co. (FLDM) Purchased by Paloma Partners Management Co

Paloma Partners Management Co purchased a new stake in shares of Fluidigm Co. (NASDAQ:FLDM) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 17,000 shares of the medical research company’s stock, valued at approximately $100,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in FLDM. Neuberger Berman Group LLC raised its position in Fluidigm by 181.6% during the 3rd quarter. Neuberger Berman Group LLC now owns 5,213,481 shares of the medical research company’s stock valued at $26,276,000 after purchasing an additional 3,362,100 shares during the last quarter. Levin Capital Strategies L.P. grew its holdings in shares of Fluidigm by 5.3% during the 4th quarter. Levin Capital Strategies L.P. now owns 9,167,070 shares of the medical research company’s stock worth $53,994,000 after acquiring an additional 463,310 shares during the period. BlackRock Inc. grew its holdings in shares of Fluidigm by 18.3% during the 4th quarter. BlackRock Inc. now owns 2,184,882 shares of the medical research company’s stock worth $12,870,000 after acquiring an additional 337,639 shares during the period. Alexandria Capital LLC purchased a new position in shares of Fluidigm during the 4th quarter worth approximately $1,111,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of Fluidigm by 70.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 370,427 shares of the medical research company’s stock worth $1,867,000 after acquiring an additional 152,588 shares during the period. 94.61% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

FLDM stock opened at $5.84 on Friday. Fluidigm Co. has a fifty-two week low of $2.52 and a fifty-two week high of $8.38. The company has a debt-to-equity ratio of 6.31, a current ratio of 2.83 and a quick ratio of 2.38.

Fluidigm (NASDAQ:FLDM) last posted its earnings results on Thursday, February 8th. The medical research company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). Fluidigm had a negative return on equity of 118.56% and a negative net margin of 59.38%. The firm had revenue of $27.75 million for the quarter, compared to analysts’ expectations of $27.14 million. During the same quarter last year, the company posted ($0.32) EPS. The firm’s revenue was up 10.6% on a year-over-year basis. research analysts expect that Fluidigm Co. will post -0.93 earnings per share for the current year.

A number of research firms have weighed in on FLDM. BidaskClub downgraded Fluidigm from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 24th. Piper Jaffray reiterated a “hold” rating and set a $6.10 target price on shares of Fluidigm in a report on Thursday, February 8th. Finally, ValuEngine downgraded Fluidigm from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd.

In other news, insider Levin Capital Strategies, L.P. bought 10,000 shares of Fluidigm stock in a transaction on Thursday, February 15th. The shares were purchased at an average price of $7.86 per share, for a total transaction of $78,600.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have acquired a total of 716,396 shares of company stock worth $4,457,414 in the last quarter. Company insiders own 4.70% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first published by WKRB News and is the sole property of of WKRB News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.wkrb13.com/2018/04/01/17000-shares-in-fluidigm-co-fldm-purchased-by-paloma-partners-management-co.html.

About Fluidigm

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Want to see what other hedge funds are holding FLDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fluidigm Co. (NASDAQ:FLDM).

Institutional Ownership by Quarter for Fluidigm (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply